Nectar Life Sciences

New York-based Nectar, part of Nectar Life Sciences, is a specialized telemedicine provider that operates a hybrid allergy care platform combining both virtual care and physical clinics. The company provides treatment for individuals suffering from environmental, pet, and food allergies. Its solutions also target individuals suffering from eczema and asthma. The vertically integrated company, which uses both telehealth and a licensed compounding pharmacy, utilizes data and clinical research to offer personalized solutions to its users.

The company offers its services D2C on a pay-per-service model.

In August 2023, the company opened i ts first physical clinic in New York, named the Nectar Allergy Center. Nectar noted that this was carried out to expand its virtual care platform to a hybrid model, offering in-person alternatives, such as consultations, lab testing, and pharmacy services, to its asynchronous virtual offering. The company also announced that it expanded its testing services to include identifying allergies to food, eczema, and asthma, and had added additional allergy specialists to its leadership team.

Funding and financials

In March 2022, it raised USD 8 million in a seed funding round led by investors Juxtapose and Obvious Ventures, who are co-building the company alongside the company’s founder. The funds were allocated to develop its proprietary and personalized allergy solutions in preparation for the planned nationwide launch of Nectar.